Senhwa Biosciences Signs Up to $16M Deal to Advance AI Drug Discovery

The agreement provides flexible access to capital to support the company’s expansion into AI drug discovery, particularly in oncology-focused research pipelines.

Taiwan-listed clinical-stage biopharmaceutical company Senhwa Biosciences has signed a Memorandum of Understanding with GEM Yield Bahamas Limited, an affiliate of the global investment firm Global Emerging Markets (GEM), for a strategic funding commitment of up to NT$500 million, approximately $16 million. The announcement was made on April 14.

The capital is intended to support three parallel tracks: advancing Senhwa’s clinical pipeline, scaling its AI-driven drug discovery platform, and pursuing global expansion. Senhwa is focused on oncology and rare diseases, with its lead candidate CX-5461 currently in Phase I/II trials for both solid tumors and hematologic malignancies.

ALSO READ: Is AI Healthcare Really Reaching Tier-2 India?

On the AI side, the company is collaborating with Y Combinator-backed startup CellType to leverage C2S (cell-to-sentence) technology, an approach that converts complex biological datasets into interpretable, structured formats to accelerate identification of combination cancer therapies. Early AI-enabled validation has reportedly shown that Senhwa’s lead candidates carry immunomodulatory potential under specific tumor microenvironment conditions, which the company says validates its “cold-to-hot tumor” strategy. The strategy aims to convert immune-unresponsive tumors into reactive states, positioning Senhwa within the emerging immuno-oncology 2.0 space.

GEM, headquartered in Luxembourg with offices in Paris, New York, and Nassau, has completed over 590 transactions across 75 countries. The MOU structure provides flexible capital access rather than an immediate transfer of funds.

Senhwa stated the partnership is also intended to lay groundwork for future international collaborations and commercialization opportunities.

The news is based on publicly available information. NervNow has not verified the details independently.

RELATED NEWS
Verily Health Raises $300M as Alphabet Cedes Control
Smart Garage Raises Rs 2.4 Cr in Pre-Series A Round
Glydways Raises $170M to Expand Robocar Networks Globally
London Fintech Round Raises $6M Seed to Automate Finance Teams